NDAORALTABLET
Approved
Sep 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
DDAVP (desmopressin acetate) by Ferring Pharmaceuticals is clinical pharmacology ddavp tablets contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. Approved for primary nocturnal enuresis. First approved in 1995.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DDAVP (desmopressin acetate) is a synthetic analogue of arginine vasopressin that acts as an antidiuretic agent. It is approved for primary nocturnal enuresis and central diabetes insipidus, reducing urinary output by increasing urine osmolality. The oral tablet formulation has low bioavailability (~5% vs intranasal) but provides antidiuretic effects lasting up to 12 hours.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%) signals declining market opportunity and likely team right-sizing.
Mechanism of Action
CLINICAL PHARMACOLOGY DDAVP Tablets contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. Central Diabetes Insipidus Dose response studies in patients with diabetes insipidus have demonstrated that oral doses of 0.025 mg to 0.4 mg…
Worked on DDAVP at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.